Single-Cell Study Pinpoints OTUD7B as a Master Switch Behind Pancreatic Cancer’s Defenses

Pancreatic ductal adenocarcinoma remains one of the most unforgiving diagnoses in medicine. Despite decades of progress in surgery, chemotherapy, radiotherapy and targeted agents, five-year survival remains dismal, and the molecular alterations that drive the disease—mutations in KRAS, TP53, CDKN2A and SMAD4—have stubbornly refused to yield effective therapies. A new study published in the Journal of Cellular and Molecular Medicine argues that part of the answer lies not in the cancer cells’ DNA alone, but in a single regulatory enzyme that appears to orchestrate how tumour cells remodel themselves and how the immune system around them is silenced. That enzyme is OTUD7B, also known as Cezanne, a member of the ovarian tumour family of deubiquitinating enzymes.

The research team assembled an unusually broad toolkit to interrogate the disease. They combined single-cell RNA sequencing of pancreatic tumour and normal tissue, high-dimensional weighted gene coexpression network analysis, nonnegative matrix factorization, bulk transcriptomic profiling from The Cancer Genome Atlas and GTEx, quantitative proteomics in CRISPR-engineered cell lines, and multiplex immunofluorescence on patient tissue sections. The goal was to move beyond the standard catalogue of mutated genes and instead map the cellular architecture and communication networks that allow pancreatic cancer to initiate, invade and evade immunity.

The single-cell analysis resolved twelve major cell lineages—T cells, B cells, macrophages, monocytes, fibroblasts, endothelial cells, epithelial cells, smooth muscle cells, NK cells, tissue stem cells, neutrophils and neurons—and then reconstructed the ligand–receptor conversations taking place among them. Macrophages, fibroblasts and epithelial cells emerged as central hubs of an intensely active communication network. In tumours, the proportions of epithelial cells, fibroblasts and macrophages expanded significantly while T cell and NK cell fractions shrank, a compositional shift the authors interpret as a transition from an immune-active to an immune-suppressive state. Interaction strength between stromal cells and immune lineages was markedly enhanced in tumour tissue compared with normal pancreas.

Within the epithelial compartment, pseudotime trajectory analysis traced a continuous transition from normal-like to malignant states, with genes such as OLFM4, ONECUT2, CDHR2 and OTUD7B changing dynamically along the path. To find the molecular programs coordinating this transformation, the team applied high-dimensional weighted gene coexpression network analysis, grouping genes into modules and identifying their hubs. One module was enriched for extracellular-matrix remodelling genes including COL1A1, COL3A1, FN1 and OTUD7B; another captured immune-regulatory chemokines such as CCL2, CXCL8 and CXCL3; a third contained epithelial markers including EPCAM, KRT19 and CDH1. Critically, the epithelial and matrix modules were strongly positively correlated, and OTUD7B sat at their intersection—positioning it as a candidate link between epithelial plasticity and stromal remodelling.

Nonnegative matrix factorization of the epithelial transcriptomes then resolved five distinct epithelial subpopulations. The most abundant in tumours was an OTUD7B-high cluster, and developmental trajectory analysis showed that OTUD7B expression peaks early in the malignant trajectory, suggesting a role in the initiation of epithelial transformation rather than merely a late consequence of it. Functional enrichment revealed that this subset is strongly associated with glycosylation-related metabolic processes and other biosynthetic pathways—hallmarks of the metabolic reprogramming that tumour cells undergo to support rapid growth and adaptation to a hostile environment.

The clinical evidence was striking. Across a pancancer analysis, OTUD7B was upregulated in multiple solid tumours, with particularly high levels in pancreatic cancer, and the finding was confirmed at both mRNA and protein level in TCGA cohorts and patient tissue sections, where staining was concentrated in tumour epithelial compartments. Expression rose with histological grade and was significantly elevated in patients with lymph node metastasis. When patients were stratified by OTUD7B levels, high expressers presented with higher grades and more advanced stages, and Kaplan–Meier analyses in both the TCGA cohort and an independent validation cohort consistently showed that high OTUD7B expression predicts poorer overall survival.

To test whether OTUD7B is merely a marker or an actual driver, the researchers generated isogenic pancreatic cancer cell lines in which the gene was deleted with CRISPR/Cas9 or forcibly overexpressed. The results were unambiguous. Loss of OTUD7B almost completely abolished anchorage-dependent colony growth, while enforced expression roughly doubled proliferation. In wound-healing assays, knockout cells barely closed the scratch, whereas overexpressing cells migrated to near-complete wound resolution. OTUD7B, in other words, behaves as a genuine engine of both proliferation and migration in pancreatic cancer cells.

Quantitative proteomics of the knockout cells revealed why the enzyme matters so much. Its removal triggered widespread proteome remodelling, with the most prominent effects converging on mitochondrial oxidative phosphorylation, NADH dehydrogenase complex assembly, mitochondrial respiratory chain organization, redox homeostasis and reactive oxygen species metabolism. Validation assays confirmed the functional consequences: OTUD7B-deficient cells accumulated malondialdehyde and intracellular ROS and showed reduced superoxide dismutase activity, while overexpression reduced lipid peroxidation, lowered ROS and restored antioxidant defences. The picture that emerges is of OTUD7B as a guardian of tumour bioenergetics, keeping pancreatic cancer cells metabolically fit and buffered against oxidative stress—capabilities that likely also shape how those cells condition their surroundings.

Perhaps the most consequential findings concern immunity. In the TCGA pancreatic cohort, OTUD7B expression correlated positively with infiltration of M2 macrophages, resting CD4 memory T cells and resting dendritic cells, and negatively with effector T-cell subsets. A broad panel of immunomodulatory genes—costimulatory and coinhibitory checkpoints, chemokines and their receptors—was predominantly positively correlated with OTUD7B, embedding it within an extensive immunoregulatory network. When the researchers applied CIBERSORT deconvolution to their proteomic data, OTUD7B depletion visibly reshaped the inferred immune landscape. And in multiplex immunofluorescence on patient tissue, OTUD7B expression tracked closely with infiltration of CD4-positive T cells and FOXP3-positive regulatory T cells: tumours with high OTUD7B showed markedly increased FOXP3 signal and higher FOXP3-to-CD4 ratios, while low-OTUD7B tumours showed reduced infiltration of these suppressive populations.

The authors synthesize these threads into a model in which an OTUD7B-high epithelial subpopulation drives a coupled ‘metabolism–stroma–immunity’ reprogramming of the pancreatic tumour microenvironment, offering a plausible explanation for the disease’s aggressiveness, poor prognosis and limited response to immune checkpoint blockade. The work is not without limitations: it is largely retrospective, lacks systematic in vivo validation, and does not yet demonstrate that directly targeting OTUD7B remodels tumour metabolism or relieves immune suppression in living models. Future efforts, the team notes, should identify the enzyme’s substrates and signalling partners, map its cell-type-specific functions in spatially resolved microenvironments, and test whether pharmacologic or genetic inhibition can convert OTUD7B from a biomarker into a tractable therapeutic vulnerability. If those efforts succeed, a deubiquitinating enzyme once studied mainly for its role in inflammatory signalling could become a key to unlocking immunotherapy for one of oncology’s most stubborn cancers.

Subject of Research: The role of OTUD7B in epithelial remodelling and immunosuppression in pancreatic ductal adenocarcinoma

Article Title: Single‐Cell Multiomics Reveals That OTUD7B Is a Central Driver of Epithelial Remodelling and the Immunosuppressive Microenvironment in Pancreatic Ductal Adenocarcinoma

Article References: Liu, X.-L., Jing‐Wang, Zhao, S.-Y., Lu‐Li, & Zhang, M.-H. (2026). Single‐Cell Multiomics Reveals That OTUD7B Is a Central Driver of Epithelial Remodelling and the Immunosuppressive Microenvironment in Pancreatic Ductal Adenocarcinoma. Journal of Cellular and Molecular Medicine, 30(19), Article e71322. https://doi.org/10.1111/jcmm.71322

Image Credits: AI Generated

DOI: 10.1111/jcmm.71322

Keywords: pancreatic cancer, OTUD7B, single-cell RNA sequencing, tumour microenvironment, regulatory T cells, proteomics, mitochondrial metabolism, deubiquitinase, immunosuppression, biomarker, hdWGCNA, prognosis